Physician profile
Jill E Gebert
NPI 1093176505
$1,240.54
in general payments reported to CMS, 2019-2025
12 companies · $964 in 2025
The $964 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.62 · 2022: $48.33 · 2023: $23.28 · 2024: $154 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $296.03 | 2024-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $154.05 | 2024-2025 | |
| Aop Health US, LLC | $141.50 | 2025 | Rapiblyk |
| Impulse Dynamics (USA) INC. | $128.61 | 2025 | Optimizer |
| Novo Nordisk INC | $117.45 | 2025 | Ozempic |
| United Therapeutics Corporation | $91.28 | 2025 | Tyvaso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.92 | 2021-2022 | |
| Pfizer INC. | $73.00 | 2024-2025 | |
| Heartflow, INC. | $47.58 | 2024-2025 | |
| Abbott Laboratories | $47.31 | 2022-2023 | Xience Sierra |
| Boston Scientific Corporation | $46.47 | 2024 | |
| Bridgebio Pharma, INC. | $22.34 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Gebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.